Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 16,996 shares of the biopharmaceutical company’s stock after selling 2,544 shares during the period. Pacer Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $12,107,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. Cornerstone Wealth Group LLC boosted its holdings in Regeneron Pharmaceuticals by 3.7% in the 4th quarter. Cornerstone Wealth Group LLC now owns 3,865 shares of the biopharmaceutical company’s stock valued at $2,753,000 after purchasing an additional 137 shares in the last quarter. KBC Group NV boosted its stake in shares of Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after buying an additional 102,198 shares in the last quarter. Blue Trust Inc. grew its holdings in Regeneron Pharmaceuticals by 39.8% during the fourth quarter. Blue Trust Inc. now owns 724 shares of the biopharmaceutical company’s stock worth $516,000 after acquiring an additional 206 shares during the period. Strategic Investment Advisors MI raised its position in Regeneron Pharmaceuticals by 8.8% in the fourth quarter. Strategic Investment Advisors MI now owns 385 shares of the biopharmaceutical company’s stock worth $275,000 after acquiring an additional 31 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in Regeneron Pharmaceuticals by 22.9% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,547 shares of the biopharmaceutical company’s stock valued at $1,814,000 after acquiring an additional 474 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on REGN. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Finally, Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,004.57.

Regeneron Pharmaceuticals Price Performance

REGN opened at $686.33 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20. The company’s 50 day simple moving average is $725.65 and its 200 day simple moving average is $933.22. The stock has a market capitalization of $75.42 billion, a PE ratio of 16.98, a P/E/G ratio of 1.59 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.